Contributors |
|
xiii | |
|
Chapter 1 Inflammation, symptoms, benefits, reaction, and biochemistry |
|
|
1 | (20) |
|
|
|
|
|
|
1 | (1) |
|
1.2 Causes and symptoms of inflammation |
|
|
1 | (1) |
|
1.3 Types of inflammation |
|
|
2 | (2) |
|
1.4 Benefits of inflammation |
|
|
4 | (6) |
|
1.5 Reactions and biochemistry |
|
|
10 | (6) |
|
|
16 | (1) |
|
|
17 | (4) |
|
Chapter 2 Molecular pharmacology of inflammation: Medicinal plants as antiinflammatory agents |
|
|
21 | (44) |
|
|
|
|
21 | (1) |
|
2.2 Antiinflammatory agent molecular targets |
|
|
22 | (1) |
|
2.3 Inflammatory mediators, receptors, and major signaling pathways |
|
|
23 | (10) |
|
2.4 Cell signaling pathways involved in inflammation |
|
|
33 | (2) |
|
2.5 Antiinflammatory potential of medicinal plants and their active constituents |
|
|
35 | (7) |
|
2.6 Inflammatory pathways as potential targets for natural bioactive compounds |
|
|
42 | (2) |
|
2.7 Antiinflammatory activity of natural bioactive compounds |
|
|
44 | (7) |
|
|
51 | (1) |
|
|
52 | (1) |
|
|
53 | (1) |
|
|
53 | (12) |
|
Chapter 3 Natural products with antiinflammatory activities against autoimmune myocarditis |
|
|
65 | (18) |
|
Akhila Nairand Sreeraj Gopi |
|
|
|
65 | (1) |
|
|
66 | (1) |
|
3.3 Etiology and pathogenesis of autoimmune myocarditis |
|
|
67 | (2) |
|
3.4 Antiinflammatory mechanism for autoimmune myocarditis |
|
|
69 | (3) |
|
3.5 Natural products renowned for antiinflammatory activity |
|
|
72 | (7) |
|
|
79 | (1) |
|
|
80 | (3) |
|
Chapter 4 Multitarget approach for natural products in inflammation |
|
|
83 | (30) |
|
|
|
|
83 | (1) |
|
4.2 Mechanisms: Mediators and pathways behind inflammation |
|
|
84 | (9) |
|
4.3 Distinct pathways behind neuroinflammation; Alzheimer's disease as a case |
|
|
93 | (2) |
|
4.4 Multitarget approach for antiinflammatory action |
|
|
95 | (1) |
|
4.5 Natural compounds with multitarget in antiinflammation |
|
|
96 | (7) |
|
4.6 Combination of phytochemicals |
|
|
103 | (1) |
|
|
104 | (1) |
|
|
105 | (8) |
|
Chapter 5 Antiinflammatory activity of natural dietary flavonoids |
|
|
113 | (14) |
|
Matheus Chiaradia de Souza |
|
|
Ana Laura Tironi de Castilho |
|
|
|
|
Leonardo de Liori Teixeira |
|
|
|
|
113 | (2) |
|
5.2 Flavonoids and cardiovascular diseases |
|
|
115 | (1) |
|
5.3 Flavonoids and diabetes mellitus |
|
|
116 | (4) |
|
5.4 Flavonoids and gastrointestinal diseases |
|
|
120 | (2) |
|
5.5 Conclusion and perspectives |
|
|
122 | (1) |
|
|
122 | (5) |
|
Chapter 6 Antiinflammatory effects of turmeric (Curcuma longa) and ginger (Zingiber officinale) |
|
|
127 | (20) |
|
|
|
|
127 | (1) |
|
|
128 | (8) |
|
6.3 Ginger (Zingiber officinale) |
|
|
136 | (6) |
|
|
142 | (1) |
|
|
142 | (5) |
|
Chapter 7 Antiinflammatory activity of Boswellia |
|
|
147 | (14) |
|
|
|
|
|
147 | (1) |
|
7.2 Taxonomy and phytochemistry |
|
|
148 | (1) |
|
7.3 Pharmacological activities of Boswellia |
|
|
148 | (2) |
|
|
150 | (2) |
|
7.5 Clinical studies of the antiinflammatory action |
|
|
152 | (2) |
|
7.6 Toxicity and side effects in clinical evaluations |
|
|
154 | (1) |
|
|
155 | (1) |
|
|
155 | (6) |
|
Chapter 8 Antiinflammatory activity of galangal |
|
|
161 | (14) |
|
|
|
|
|
161 | (1) |
|
|
162 | (2) |
|
8.3 Mechanism of antiinflammatory pathway |
|
|
164 | (1) |
|
8.4 Pharmacological activities |
|
|
165 | (3) |
|
8.5 Usage in traditional systems |
|
|
168 | (1) |
|
|
169 | (1) |
|
|
169 | (1) |
|
|
170 | (5) |
|
Chapter 9 Antiinflammatory natural products from marine algae |
|
|
175 | (30) |
|
|
|
|
|
175 | (2) |
|
|
177 | (2) |
|
9.3 Algal natural products with antiinflammatory activity |
|
|
179 | (13) |
|
|
192 | (1) |
|
|
192 | (1) |
|
|
192 | (13) |
|
Chapter 10 Medicinal plants and their potential use in the treatment of rheumatic diseases |
|
|
205 | (30) |
|
|
|
|
|
205 | (1) |
|
10.2 Herbal products currently used in antiarthritic therapy |
|
|
206 | (19) |
|
10.3 Conclusion and perspectives |
|
|
225 | (1) |
|
|
226 | (9) |
|
Chapter 11 Natural product-derived drugs for the treatment of inflammatory bowel diseases (IBD) |
|
|
235 | (26) |
|
|
|
|
Jonnacar S. San Sebastian |
|
|
|
|
|
|
235 | (1) |
|
|
236 | (1) |
|
|
236 | (4) |
|
11.4 The role of natural products on IBD |
|
|
240 | (2) |
|
11.5 Natural products for ulcerative colitis and Crohn's disease |
|
|
242 | (11) |
|
11.6 Conclusion remarks and future perspective |
|
|
253 | (1) |
|
|
254 | (7) |
|
Chapter 12 Smart drug delivery systems of natural products for inflammation: From fundamentals to the clinic |
|
|
261 | (22) |
|
|
|
|
|
|
261 | (1) |
|
12.2 Stimuli-responsive drug delivery system |
|
|
262 | (17) |
|
|
279 | (1) |
|
|
280 | (3) |
|
Chapter 13 Systems pharmacology and molecular docking strategies prioritize natural molecules as antiinflammatory agents |
|
|
283 | (38) |
|
|
|
|
283 | (6) |
|
13.2 Systems pharmacology and anti-inflammatory agents |
|
|
289 | (2) |
|
13.3 Computational methodologies and molecular docking studies with natural compounds |
|
|
291 | (1) |
|
13.4 Inflammatory pathway network and key node targets of antiinflammatory agents |
|
|
292 | (3) |
|
13.5 Prioritization strategy and systems pharmacology approach for screening of potential therapeutic agents |
|
|
295 | (2) |
|
13.6 Natural compounds and their interactions in the inflammatory pathway network and prioritization as antiinflammatory agents |
|
|
297 | (14) |
|
|
311 | (1) |
|
|
312 | (9) |
|
Chapter 14 Bioavailability, pharmacokinetic, pharmacodynamic, and clinical studies of natural products on their antiinflammatory activities |
|
|
321 | (38) |
|
|
|
|
|
321 | (1) |
|
14.2 Antiinflammatory activities of natural products |
|
|
322 | (31) |
|
|
353 | (1) |
|
|
354 | (5) |
|
Chapter 15 Supplements and diets for antiinflammation |
|
|
359 | (18) |
|
|
|
|
359 | (1) |
|
15.2 Types of inflammatory |
|
|
359 | (2) |
|
15.3 Antiinflammatory supplements |
|
|
361 | (6) |
|
15.4 Role of diet in body inflammation |
|
|
367 | (2) |
|
15.5 Nutrient effects on chronic inflammation |
|
|
369 | (1) |
|
|
370 | (1) |
|
|
371 | (6) |
|
Chapter 16 Values of natural products to future anti-inflammatory pharmaceutical discovery |
|
|
377 | (30) |
|
|
|
|
377 | (2) |
|
16.2 Inflammatory mediators |
|
|
379 | (1) |
|
16.3 Antiinflammatory therapy and response |
|
|
379 | (1) |
|
16.4 Nonsteroidal antiinflammatory drugs vs inflammation |
|
|
380 | (1) |
|
16.5 Biodiversity of plant natural products |
|
|
381 | (1) |
|
16.6 Medicinal plants as gift of nature |
|
|
381 | (2) |
|
16.7 Herbal remedies in traditional medication for inflammation |
|
|
383 | (1) |
|
16.8 Ayurvedic formulation for inflammation |
|
|
384 | (1) |
|
16.9 Natural products--A promising antiinflammatory pharmaceutical drug discovery |
|
|
385 | (9) |
|
16.10 Major challenges in upgrading natural products |
|
|
394 | (1) |
|
16.11 Future prospective and conclusions |
|
|
395 | (1) |
|
|
395 | (12) |
|
Chapter 17 Identification of toxicology biomarker and evaluation of toxicity of natural products by metabolomic applications |
|
|
407 | (30) |
|
|
|
|
|
|
407 | (3) |
|
17.2 Metabolomic technology |
|
|
410 | (1) |
|
|
411 | (1) |
|
|
412 | (3) |
|
17.5 Metabolomics in toxicity evaluation and biomarker identification of natural products |
|
|
415 | (15) |
|
17.6 Concluding remarks and perspectives |
|
|
430 | (1) |
|
|
431 | (6) |
Index |
|
437 | |